Conference Coverage

Why Incorporating Obstetric History Matters for CVD Risk Management in Autoimmune Diseases


 

The Case for Treatment During Pregnancy

Prophylaxis against pregnancy complications in patients with autoimmune disease may be achievable, Taryn Youngstein, MBBS, consultant rheumatologist and codirector of the Centre of Excellence in Vasculitis Research, Imperial College London, London, England, told this news organization after Dr. Sammaritano’s presentation. At the 2023 American College of Rheumatology Annual Meeting, her group reported the safety and effectiveness of continuing tocilizumab in pregnant women with Takayasu arteritis, a large-vessel vasculitis predominantly affecting women of reproductive age.

“What traditionally happens is you would stop the biologic particularly before the third trimester because of safety and concerns that the monoclonal antibody is actively transported across the placenta, which means the baby gets much more concentration of the drug than the mum,” Dr. Youngstein said.

It’s a situation physicians must monitor closely, she said. “The mum is donating their immune system to the baby, but they’re also donating drug.”

“In high-risk patients, we would share decision-making with the patient,” Dr. Youngstein continued. “We have decided it’s too high of a risk for us to stop the drug, so we have been continuing the interleukin-6 [IL-6] inhibitor throughout the entire pregnancy.”

The data from Dr. Youngstein’s group showed that pregnant women with Takayasu arteritis who continued IL-6 inhibition therapy all carried to term with healthy births.

“We’ve shown that it’s relatively safe to do that, but you have to be very careful in monitoring the baby,” she said. This includes not giving the infant any live vaccines at birth because it will have the high levels of IL-6 inhibition, she said.

Dr. Sammaritano and Dr. Youngstein had no relevant financial relationships to disclose.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

New Analysis Defines Three Distinct Sjögren Syndrome Subgroups
MDedge Internal Medicine
Multiple Social Disadvantages Linked to Progressively Worse JIA and Pediatric Lupus
MDedge Internal Medicine
FDA OKs First-in-Class Agent for Pulmonary Arterial Hypertension
MDedge Internal Medicine
Autoimmunity’s Female Bias and the Mysteries of Xist
MDedge Internal Medicine
Tuberculosis Screening Gaps Persist in New DMARD Users
MDedge Internal Medicine
Barcelona’s Best: Vasculitis Treatment Studies on Stopping Steroids, Abatacept, Plasma Exchange, Vaccination
MDedge Internal Medicine
Combined Pediatric Derm-Rheum Clinics Supported by Survey Respondents
MDedge Internal Medicine
New British Behçet’s Disease Guidelines Emphasize Multidisciplinary Management
MDedge Internal Medicine
Updated Sjögren Disease Guideline Advises Doing ‘the Little Things Well’
MDedge Internal Medicine
bDMARDs Preserve Renal Function in Most Patients With AA Amyloidosis
MDedge Internal Medicine